Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program.

Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C.

J Clin Oncol. 2014 Jul 7. pii: JCO.2013.54.9329. [Epub ahead of print]

PMID:
25002720
[PubMed - as supplied by publisher]
2.

Response.

Smith CG, West H, Harris R, Idziaszczyk S, Maughan TS, Kaplan R, Richman S, Quirke P, Seymour M, Moskvina V, Steinke V, Propping P, Hes FJ, Wijnen J, Cheadle JP.

J Natl Cancer Inst. 2014 Apr 26;106(5). pii: dju087. doi: 10.1093/jnci/dju087. No abstract available.

PMID:
24771876
[PubMed - indexed for MEDLINE]
3.

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?

Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, Wilson RH, Jasani B, Taylor GR, Williams GT, Sampson JR, Seymour MT, Nichols LL, Kenny SL, Nelson A, Sampson CM, Hodgkinson E, Bridgewater JA, Furniss DL, Roy R, Pope MJ, Pope JK, Parmar M, Quirke P, Kaplan R.

Br J Cancer. 2014 Apr 29;110(9):2178-86. doi: 10.1038/bjc.2014.182. Epub 2014 Apr 17.

PMID:
24743706
[PubMed - indexed for MEDLINE]
4.

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.

Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T, Butler R, Stanton L, Dixon E, Little L, Bowers M, Pugh S, Garden OJ, Cunningham D, Maughan T, Bridgewater J.

Lancet Oncol. 2014 May;15(6):601-11. doi: 10.1016/S1470-2045(14)70105-6. Epub 2014 Apr 7. Erratum in: Lancet Oncol. 2014 Jun;15(7):e253.

PMID:
24717919
[PubMed - indexed for MEDLINE]
5.

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.

Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, Sydes B, Madi A, Sizer B, Lowdell C, Middleton G, Butler R, Kaplan R, Maughan T; COIN-B investigators.

Lancet Oncol. 2014 May;15(6):631-9. doi: 10.1016/S1470-2045(14)70106-8. Epub 2014 Apr 3.

PMID:
24703531
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.

Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J, Maughan T, Castillo MG, Iveson T, Yin D, Green S, Bergsland EK.

Cancer Chemother Pharmacol. 2014 Apr;73(4):695-702. doi: 10.1007/s00280-014-2391-2. Epub 2014 Feb 1.

PMID:
24488322
[PubMed - in process]
7.

Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study.

Taylor FG, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, Sebag-Montefiore D, Tekkis P, Brown G; Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Study Group.

J Clin Oncol. 2014 Jan 1;32(1):34-43. doi: 10.1200/JCO.2012.45.3258. Epub 2013 Nov 25.

PMID:
24276776
[PubMed - indexed for MEDLINE]
8.

Evaluating many treatments and biomarkers in oncology: a new design.

Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, Parmar M.

J Clin Oncol. 2013 Dec 20;31(36):4562-8. doi: 10.1200/JCO.2013.50.7905. Epub 2013 Nov 18.

PMID:
24248692
[PubMed - indexed for MEDLINE]
9.

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.

Türbachova I, Schwachula T, Vasconcelos I, Mustea A, Baldinger T, Jones KA, Bujard H, Olek A, Olek K, Gellhaus K, Braicu I, Könsgen D, Fryer C, Ravot E, Hellwag A, Westerfeld N, Gruss OJ, Meissner M, Hasan MT, Weber M, Hoffmüller U, Zimmermann S, Loddenkemper C, Mahner S, Babel N, Berns E, Adams R, Zeilinger R, Baron U, Vergote I, Maughan T, Marme F, Dickhaus T, Sehouli J, Olek S.

Epigenetics. 2013 Nov;8(11):1226-35. doi: 10.4161/epi.26334. Epub 2013 Sep 26.

PMID:
24071829
[PubMed - in process]
Free Article
10.

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).

Middleton G, Brown S, Lowe C, Maughan T, Gwyther S, Oliver A, Richman S, Blake D, Napp V, Marshall H, Wadsley J, Maisey N, Chau I, Hill M, Gollins S, Myint S, Slater S, Wagstaff J, Bridgewater J, Seymour M.

Eur J Cancer. 2013 Nov;49(16):3507-16. doi: 10.1016/j.ejca.2013.06.017. Epub 2013 Aug 13.

PMID:
23953030
[PubMed - indexed for MEDLINE]
11.

Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.

Smith CG, West H, Harris R, Idziaszczyk S, Maughan TS, Kaplan R, Richman S, Quirke P, Seymour M, Moskvina V, Steinke V, Propping P, Hes FJ, Wijnen J, Cheadle JP.

J Natl Cancer Inst. 2013 Aug 21;105(16):1249-53. doi: 10.1093/jnci/djt183. Epub 2013 Jul 12.

PMID:
23852950
[PubMed - indexed for MEDLINE]
12.

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.

Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, Harris R, James MD, Meade A, Jasani B, Adams RA, Kenny S, Kaplan R, Lambrechts D, Cheadle JP.

Clin Cancer Res. 2013 Aug 1;19(15):4104-13. doi: 10.1158/1078-0432.CCR-12-2581. Epub 2013 Jun 5.

PMID:
23741067
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.

Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P.

Lancet Oncol. 2013 Jul;14(8):749-59. doi: 10.1016/S1470-2045(13)70163-3. Epub 2013 May 29.

PMID:
23725851
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G.

Lancet Oncol. 2013 Jun;14(7):627-37. doi: 10.1016/S1470-2045(13)70136-0. Epub 2013 Apr 25.

PMID:
23623280
[PubMed - indexed for MEDLINE]
Free Article
15.

Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer.

Smith CG, Naven M, Harris R, Colley J, West H, Li N, Liu Y, Adams R, Maughan TS, Nichols L, Kaplan R, Wagner MJ, McLeod HL, Cheadle JP.

Hum Mutat. 2013 Jul;34(7):1026-34. doi: 10.1002/humu.22333. Epub 2013 May 20.

PMID:
23585368
[PubMed - indexed for MEDLINE]
16.

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D.

Lancet Oncol. 2013 May;14(6):516-24. doi: 10.1016/S1470-2045(13)70086-X. Epub 2013 Apr 9.

PMID:
23578724
[PubMed - indexed for MEDLINE]
Free Article
17.

Drivers and barriers to patient participation in RCTs.

Jenkins V, Farewell V, Farewell D, Darmanin J, Wagstaff J, Langridge C, Fallowfield L; TTT Steering committee.

Br J Cancer. 2013 Apr 16;108(7):1402-7. doi: 10.1038/bjc.2013.113. Epub 2013 Mar 19.

PMID:
23511558
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.

Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T.

Lancet Oncol. 2013 Apr;14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6.

PMID:
23474363
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Teams Talking Trials: results of an RCT to improve the communication of cancer teams about treatment trials.

Jenkins VA, Farewell D, Farewell V, Batt L, Wagstaff J, Langridge C, Fallowfield LJ; Teams Talking Trials Steering Committee.

Contemp Clin Trials. 2013 May;35(1):43-51. doi: 10.1016/j.cct.2013.02.003. Epub 2013 Feb 9.

PMID:
23403074
[PubMed - indexed for MEDLINE]
20.

Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.

Powell JR, Dojcinov S, King L, Wosniak S, Gerry S, Casbard A, Bailey H, Gallop-Evans E, Maughan T.

Leuk Lymphoma. 2013 May;54(5):959-66. doi: 10.3109/10428194.2012.733875. Epub 2012 Oct 16.

PMID:
23020605
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk